Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

E. Gallant, Joel; DeJesus, Edwin; Ramón Arribas, José; Pozniak, Anton; Gazzard, Brian; Campo, Rafael; Lu, Biao; J. McColl, Damian; L. Chuck, Steven; Enejosa, Jeffrey; J. Toole, John; Cheng, Andrew

doi:10.1056/nejmoa051871

Public

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

Published in New England Journal of Medicine • Jan 18, 2006

Authors:

Joel E. Gallant

Edwin DeJesus

José Ramón Arribas

Abstract

BACKGROUND: Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere. METHODS: We conducted an open-label, noninferiority study involving 517 patients with HIV infection who h...

Subject

Emtricitabine

Efavirenz

Lamivudine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!